Vertex

Cintas Builds Generative AI-Powered Internal Knowledge Center with Google Cloud

Retrieved on: 
火曜日, 4月 9, 2024
Cloud, Google Cloud, Partnership, LAS, A.I, Vertex, Workforce, CTAS, Sales

CINCINNATI, April 9, 2024 /PRNewswire/ -- Cloud Next '24, LAS VEGAS -- Cintas Corporation (NASDAQ: CTAS), a leading provider of business to business services, and Google Cloud today announced an expanded partnership to support Cintas' ongoing digital transformation. Cintas will leverage Vertex AI–Google Cloud's generative AI (gen AI) platform–to develop an internal knowledge center that will empower its employee-partners to more quickly and easily source key information that elevates the Cintas customer experience.

Key Points: 
  • Cintas will leverage Vertex AI–Google Cloud's generative AI (gen AI) platform–to develop an internal knowledge center that will empower its employee-partners to more quickly and easily source key information that elevates the Cintas customer experience.
  • "The new Cintas internal knowledge center, powered by Google Cloud's generative AI capabilities, will help its employees–partners easily derive key insights, identify opportunities, and reduce errors—all while improving the customer experience."
  • Cintas first realized the benefits of Google Cloud in 2020 when it deployed Kubernetes to modernize its application development.
  • Then, in 2023, Cintas completed the migration of its legacy, on-premises enterprise applications to Google Cloud.

Vertex Advances Inaxaplin (VX-147) into Phase 3 Portion of Adaptive Phase 2/3 Clinical Trial for the Treatment of APOL1-Mediated Kidney Disease

Retrieved on: 
月曜日, 4月 1, 2024
Biotechnology, Other Health, Health, Pharmaceutical, Clinical Trials, BTD, Orphan drug, APOL1, RPD, Disease, Patient, Apolipoprotein L1, FSGS, Standard of care, EMA, UPCR, European Medicines Agency, Vertex Pharmaceuticals, Clinical trial, Vertex, Proteinuria, Food, FDA, IDMC, VRTX, Pharmaceutical industry

The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two variants in the APOL1 gene, known as AMKD.

Key Points: 
  • The clinical trial is designed to assess the impact of inaxaplin on kidney function and proteinuria for people living with proteinuric kidney disease mediated by two variants in the APOL1 gene, known as AMKD.
  • In addition, the trial has been expanded to include adolescents with AMKD ages 10 to 17 years.
  • The IDMC also recommended enrolling adolescents with AMKD ages 10 to 17 years in the Phase 3 portion of the study.
  • The European Medicines Agency (EMA) has also granted inaxaplin Priority Medicines (PRIME) and Orphan Drug designations for AMKD.

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-407 for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Retrieved on: 
木曜日, 3月 21, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, FDA, Clinical Trials, Death, Autosome, VRTX, Growth, Disease, PC1, Patient, Kidney failure, Kidney transplantation, Polycystic kidney disease, IND, Vertex Pharmaceuticals, PKD1, Vertex, ADPKD, Dialysis, Cystic fibrosis, Food, Pharmaceutical industry

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.

Key Points: 
  • Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has cleared the Investigational New Drug Application (IND) for VX-407, an investigational first-in-class small molecule corrector that targets the underlying cause of autosomal dominant polycystic kidney disease (ADPKD) in patients with a subset of PKD1 genetic variants.
  • ADPKD is the most common inherited kidney disease, with an estimated 250,000 people in the U.S. and Europe living with ADPKD; however, there are no treatments currently available that address the underlying causal biology of the disease.
  • ADPKD is a life-shortening genetic kidney disease characterized by the growth of numerous kidney-enlarging cysts that impair kidney function and can ultimately lead to kidney failure, requiring dialysis or kidney transplantation, and premature death.
  • The majority of ADPKD cases are caused by variants in the PKD1 gene, which encodes the polycystin 1 (PC1) protein.

UKG Partners of the Year Help Create Great Workplaces

Retrieved on: 
水曜日, 3月 13, 2024
Software, Human Resources, Internet, Artificial Intelligence, Data Management, Professional Services, Technology, Apps, Applications, Cloud, UKG, Automation, Certification, Partner, HR, Culture, IVR, Organization, Communication, Partnership, Strategic planning, Acquisition, Investment, HCM, PayActiv, Vertex, Workforce, Accenture, Workplace, Jubilant, G2, Work

“Highly extensible technology, a deep understanding of culture, and the collaborative spirit of our entire partner network help customers keep workplaces centered on people, not processes.”

Key Points: 
  • “Highly extensible technology, a deep understanding of culture, and the collaborative spirit of our entire partner network help customers keep workplaces centered on people, not processes.”
    Each year, UKG recognizes partners for going above and beyond in their efforts to create exceptional experiences for UKG customers and their employees.
  • This includes technology partners that deliver new innovations or extensible solutions that enhance IT experiences, and services partners that implement UKG suites as a cornerstone of culture and workplace transformations.
  • The UKG 2023 Technology and Services Partners of the Year:
    Innovator of the Year recognizes partners that showcase innovative technology, creative solutions, and strategic planning and execution for joint customers.
  • Technology Partner Recipient: CloudApper , for its suite of generative AI, no-code, and low-code tools that help UKG customers quickly create apps and integrations.

BLACK HEALTH MATTERS TO HOST FREE SPRING HEALTH SUMMIT AND EXPO IN WASHINGTON, D.C.

Retrieved on: 
水曜日, 4月 3, 2024
Kidney, Glucose, LDL, Exercise, Hepatitis C, Jabari, Black, BMS, National Pan-Hellenic Council, Patient, Vertex, Lunch, PSA, Legislation, Education, Gallaudet University, Omega Psi Phi, Incontinence, Johnson & Johnson, Cholesterol, WRC-TV, Triglyceride, Hypertension, Sanofi, Doctor of Pharmacy, Leukemia, Memory, Food, HDL, Phi Beta Sigma, Health, COVID-19 vaccine, Conference, BHM, COVID-19, All My Children, Howard University Hospital, Breakfast, Kidney disease, Diet, Guru, Sibley Memorial Hospital, Pharmaceutical industry

WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13. As part of the award-winning health summit series, the free, one-day event will be held at the Kellogg Conference Hotel at Gallaudet University at 800 Florida Avenue, N.E., Washington, DC 20002 and includes celebrity hosts, medical professionals, health screenings, prizes, breakfast, and lunch. The event is open to the public and will begin at 8:30 a.m. with breakfast and conclude at 3:30 p.m.

Key Points: 
  • Popular health-focused event to feature free screenings, conversations with experts and celebrities
    WASHINGTON, April 3, 2024 /PRNewswire/ -- Black Health Matters (BHM) – a leading nonprofit health advocacy organization that provides health and wellness information to the Black community – will host its annual Black Health Matters Spring Health Summit and Expo in Washington, D.C. on Saturday, April 13.
  • After over a decade of hosting the popular health-focused summits, this will be the first in Washington, D.C. for Black Health Matters.
  • The Black Health Matters Spring Summit & Expo is sponsored by leading health organizations including Sanofi|Regeneron, Johnson & Johnson Health Care Systems, Johnson & Johnson Innovative Medicine, Research Includes Me, BMS, Sanofi, argenx, Vertex and CISCRP.
  • Notable partners are Howard University Hospital; DC Department of Health Care Finance; Precision Wellness; and American Association of Kidney Patients.

Trina Solar's full range of n-type Vertex modules obtain Carbon Footprint certification by UL Solutions

Retrieved on: 
月曜日, 3月 11, 2024
Carbon, Certification, Solar energy, ESG, Information technology, Climate change mitigation, Carbon footprint, EPD, Vertex, CFP, Ministry, ISO, PV, Renewable energy

CHANGZHOU, China, March 11, 2024 /PRNewswire/ -- Trina Solar, a global leader in smart PV and energy storage solutions, has announced that its full range n-type modules, including Vertex N 720W series modules, Vertex N 625W modules and Vertex S+ modules, have been granted Carbon Footprint of Products Verification by UL Solutions.

Key Points: 
  • CHANGZHOU, China, March 11, 2024 /PRNewswire/ -- Trina Solar, a global leader in smart PV and energy storage solutions, has announced that its full range n-type modules, including Vertex N 720W series modules, Vertex N 625W modules and Vertex S+ modules, have been granted Carbon Footprint of Products Verification by UL Solutions.
  • After verifying the carbon footprint of modules, the carbon footprint of Trina Solar's Vertex N 720W series modules, Vertex N 625W modules and Vertex S+ modules can be as low as 400kg/kW.
  • Trina Solar has also obtained EPD certifications from UL Solutions and gained registered EPD Italy certification for the outstanding performance of its Vertex series in December.
  • Zhao Jinqiang, president of Trina Solar's cell and module business unit, said: "Trina Solar is continuously improving its ESG governance structure.

Trina Solar's full range of n-type Vertex modules obtain Carbon Footprint certification by UL Solutions

Retrieved on: 
月曜日, 3月 11, 2024
Carbon, Certification, Solar energy, ESG, Information technology, Climate change mitigation, Carbon footprint, EPD, Vertex, CFP, Ministry, ISO, PV, Renewable energy

CHANGZHOU, China, March 11, 2024 /PRNewswire/ -- Trina Solar, a global leader in smart PV and energy storage solutions, has announced that its full range n-type modules, including Vertex N 720W series modules, Vertex N 625W modules and Vertex S+ modules, have been granted Carbon Footprint of Products Verification by UL Solutions.

Key Points: 
  • CHANGZHOU, China, March 11, 2024 /PRNewswire/ -- Trina Solar, a global leader in smart PV and energy storage solutions, has announced that its full range n-type modules, including Vertex N 720W series modules, Vertex N 625W modules and Vertex S+ modules, have been granted Carbon Footprint of Products Verification by UL Solutions.
  • After verifying the carbon footprint of modules, the carbon footprint of Trina Solar's Vertex N 720W series modules, Vertex N 625W modules and Vertex S+ modules can be as low as 400kg/kW.
  • Trina Solar has also obtained EPD certifications from UL Solutions and gained registered EPD Italy certification for the outstanding performance of its Vertex series in December.
  • Zhao Jinqiang, president of Trina Solar's cell and module business unit, said: "Trina Solar is continuously improving its ESG governance structure.

Xometry Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
木曜日, 2月 29, 2024
Spend, Cloud, CNC, Acquisition, Google Cloud, International, Total, AI, Investment, Supply chain, XMTR, Growth, Sale, Vertex, AS9100, Computer-aided design, Advertising, CAD, Deposition, IATF, Depreciation, Certification, Software, Instant, Measurement, Partnership, Video game

NORTH BETHESDA, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) --  Xometry, Inc. (NASDAQ:XMTR), the global AI-powered marketplace connecting enterprise buyers with suppliers of manufacturing services, today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • NORTH BETHESDA, Md., Feb. 29, 2024 (GLOBE NEWSWIRE) --  Xometry, Inc. (NASDAQ:XMTR), the global AI-powered marketplace connecting enterprise buyers with suppliers of manufacturing services, today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • “In Q4 2023, we delivered record financial results including our highest revenue and gross profit in Xometry history,“ said Randy Altschuler, Xometry’s CEO.
  • Marketplace revenue for the fourth quarter of 2023 was $112 million, an increase of 42% year-over-year.
  • Total gross profit for the fourth quarter 2023 was $49.1 million, an increase of 39% year-over-year.

Vertex Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
木曜日, 2月 29, 2024
Cloud, Acquisition, Revenue stream, Total, DeStefano, Growth, Vertex, Adjustment, Chairperson, GAAP, Cloud computing, EPS, Risk, Depreciation

KING OF PRUSSIA, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its fourth quarter and full year ended December 31, 2023.

Key Points: 
  • KING OF PRUSSIA, Pa., Feb. 29, 2024 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) (“Vertex” or the “Company”), a leading global provider of indirect tax solutions, today announced financial results for its fourth quarter and full year ended December 31, 2023.
  • “The Vertex execution engine delivered exceptionally strong financial results in the fourth quarter,” stated David DeStefano, President, Chief Executive Officer, and Chairperson of the Board.
  • Average Annual Revenue per direct customer (“AARPC”) was $118,910 at December 31, 2023, compared to $100,500 at December 31, 2022 and $112,690 at September 30, 2023.
  • Vertex will host a conference call at 8:30 a.m. Eastern Time today, February 29, 2024, to discuss its fourth quarter and full year 2023 financial results.

Vertex Energy Announces Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
木曜日, 2月 29, 2024
Environment, Utilities, Oil, Gas, Alternative Energy, Green Technology, Energy, Total, Soybean, LCFS, Growth, Gasoline, Vertex, Sale, Adjustment, Carbon, Rapeseed oil, KPI, Fuel oil, Pharmaceutical industry

Vertex Energy, Inc. (NASDAQ: VTNR) (“Vertex” or the “Company”), a leading specialty refiner and marketer of high-quality refined products, today announced its financial results for the fourth quarter ended December 31, 2023.

Key Points: 
  • Vertex Energy, Inc. (NASDAQ: VTNR) (“Vertex” or the “Company”), a leading specialty refiner and marketer of high-quality refined products, today announced its financial results for the fourth quarter ended December 31, 2023.
  • The Company will host a conference call to discuss fourth quarter 2023 results today, at 8:30 A.M. Eastern Time.
  • Vertex reported fourth quarter 2023 net loss attributable to the Company of ($63.9) million, or ($0.84) per fully-diluted share, versus net income attributable to the Company of $44.4 million, or $0.07 per fully-diluted share for the fourth quarter of 2022.
  • As previously communicated, the Company expected that the initial default level LCFS credits would be applied to all volumes of renewable diesel produced during the third and fourth quarter of 2023 and to contribute to financial results in the fourth quarter.